SCHEMBL6716711

SCHEMBL6716711

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccc(C2=NCCc3ccc(F)cc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 2/20 0.44
GSPT1 P15170 1/20 0.42
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
HSD11B1 P28845 6/20 0.40
EDNRB P24530 2/20 0.39
EDNRA P25101 2/20 0.39
SLC40A1 Q9NP59 1/20 0.37
SGK1 O00141 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
PKLR P30613 1/20 0.37
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RORC P51449 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CG P48736 1/20 0.36
PIK3C3 Q8NEB9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714977 0.93 GSPT1 (0.45) MAPK10GSPT1DDB1CRBNHSD11B1
SCHEMBL6720515 0.92 MAPK10 (0.46) MAPK10GSPT1DDB1CRBNHSD11B1
SCHEMBL6724595 0.91 GSPT1 (0.44) MAPK10GSPT1DDB1CRBNHSD11B1
SCHEMBL6716845 0.88 GSPT1 (0.46) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6717898 0.86 SGK1 (0.46) MAPK10SGK1NPSR1LMNASMN1; SMN2
SCHEMBL6720455 0.85 MAPK10 (0.46) MAPK10GSPT1DDB1CRBNHSD11B1
SCHEMBL6716714 0.84 GSPT1 (0.45) MAPK10GSPT1DDB1CRBNHSD11B1
SCHEMBL6716965 0.83 GSPT1 (0.43) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6716678 0.82 ITGA1 (0.46) MAPK10SGK1NPSR1LMNASMN1; SMN2
SCHEMBL7209077 0.82 MAPK10 (0.43) MAPK10SGK1LMNAPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A MAPK10 1836/4885GSPT1 1717/4885DDB1 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.